| Class | Anorectic |
|---|---|
| Chemistry |
Phenylethylamine |
| Routes of administration |
oral |
| Absorption |
Almost 100% bioavailability |
| Solubility |
pKa = 10.11, good water solubility; enough lipid solubility to cross the blood-brain barrier |
| Distribution |
VOD= 5L/kg, 17.50% protein-bound |
| Metabolism |
The majority of a dose (70-80%, some sources estimate higher) is excreted unchanged in urine; the portion which is metabolised is metabolised primarily by CYP3A4. |
| Elimination |
Minimal free drug is eliminated in the urine |
| Time course of action |
Half-life ~20 hours |
| Target receptor |
The intracellular receptor TAAR1, which is activated and causes the internalisation or transporter reversal of DAT, NET and SERT (as well as vesicular monoamine transporter VMAT2 and MAO which are inhibited) |
| Mechanism of action |
By increasing the synaptic concentration of noradrenaline and dopamine, amphetamine-like drugs acts as indirect sympathomimetics. Because they act centrally, this effect translates into increased alertness and arousal, as well as broadly adrenaline-like peripheral effects. Phentermine is a modified cogener of amphetamine and has less effects on dopamine activity, which is thought to reduce its abuse potential. |
| Clinical effects |
Increased alertness as well as nausea, vomiting, abdominal cramps, hypertension, tachycardia, exacerbation of motor tics, lower seizure threshold. Anorexia is an expected and desired effect. |
| Literature reference |
Lewis et al, 2024 |
| CICM details of understanding | Not specifically listed in the CICM syllabus |
| Mentioned around Deranged Physiology | |
| Related SAQs |